Overview

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.

Phase:

Phase 2

Details

Lead Sponsor:

London School of Hygiene and Tropical Medicine

Collaborators:

Innovative Medicines Initiative
University of Sierra Leone

Treatments:

Vaccines